All News

QD Clinic - RA and LFTs NAFLD, NASH and Risks with DMARDs and MTX https://t.co/LYV9WycEjz https://t.co/CMGtU4vclY

Links:

Dr. John Cush RheumNow ( View Tweet)
#RA associated interstifial lung dz has incidence of 1-5 per 1,000 PYs and prevalence as high as 67%; risk factors; age, male sex, Dz duration, CCP Abs; w/ age as best predictor of mortality. There is no clear drug interventions that helps RA-ILD https://t.co/zJvWqt0w6L

Links:

Dr. John Cush RheumNow ( View Tweet)

Download available--Difficult RA Defined https://t.co/6WGMEiwiUk

Links:

Dr. John Cush RheumNow ( View Tweet)

RheumNow Podcast square

RheumNow Podcast – Pounds of Prevention (3.5.2021)

d Jack Cush, MD

Dr. Jack Cush reviews and discusses nearly a dozen news reports and journal articles from the past week on RheumNow.com.

Read Article
News Feature: Paucity of Effectiveness Research on Telemedicine in RA https://t.co/AoKnIZCYgA https://t.co/MCBfVoEvBX

Links:

Dr. John Cush RheumNow ( View Tweet)
While RA incurrs a 2 fold risk of CHF; the use of HCQ does not add to a CHF risk. Mayo nested case-control study, compared RA w/ CHF vs nonCHF RA pts, showing HCQ use, nor duration of use, failed to increase CHF (OR: 0.96).https://t.co/Tx9jr07C7i

Links:

Dr. John Cush RheumNow ( View Tweet)

Telemedicine.MD.Computer.phone (keep)

Paucity of Effectiveness Research on Telemedicine in RA

d Jack Cush, MD

A systematic review of telehealth in delivering equivalent care in RA patients demonstrates there is limited evidence that virtual RA care is equivalent to conventional face-to-face care. Despite current widespread use, there is a great need for credible well-designed research that will address comparable patient outcomes, implementation strategies and long‐term health system consequences. 

Read Article
620 RA patients from Nordic biologics registers started a non-TNFi as 1steverr bDMARD but later switched to a 2nd bDMARD (ABA 86, RTX 40, TCZ 67 TNFi 427). Retention was 70% @ 6 mos & 50% @12 mos. 30-40% on 2nd bDMARD reached LDAS or remission https://t.co/u8BQn0rYca

Links:

Dr. John Cush RheumNow ( View Tweet)

Compared with no statin use; statin use in RA pts is assoc w/ 28% lower mortality risk. Population study of 19,614 RA pts w/ incident statin use, compared 1,883 statin users vs 1,883 nonusers. All-cause mortality was lower (HR 0.72;0.56-0.91) w/ statins https://t.co/onMlWoVdPL

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Measureable Benefits to Treat-to-Target Management in RA https://t.co/iAvLWJGTXp https://t.co/NfNj3MWznI

Links:

Dr. John Cush RheumNow ( View Tweet)
Pooled analysis of 16 observational RA registries (27 583 patients) shows that seropositivity was associated with better remission, LDAS and withdrawal rates for RTX and ABA, but not TNF inhibitors. https://t.co/aNphJpB7JB

Links:

Dr. John Cush RheumNow ( View Tweet)

QD Clinic - RA or Not? Lessons from the clinic. Enough serology, but not enough joints - when does it become RA? https://t.co/akklOklPee

Links:

Dr. John Cush RheumNow ( View Tweet)

We are three weeks out from RheumNow Live. Are you planning on attending? https://t.co/vJlU0Z3Q3x

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Measurable Benefits withTreat-to-Target Management in RA https://t.co/iAvLWJGTXp https://t.co/XNtGhoWs5I

Links:

Dr. John Cush RheumNow ( View Tweet)
We are excited to share that Roy Fleischmann will be leading a discussion on future therapy in RA at RheumnNow Live next month. Sign up today to attend in person or virtually. https://t.co/vJlU0Z3Q3x https://t.co/uN1MrzWZA9

Links:

Dr. John Cush RheumNow ( View Tweet)
T2T.RA_.jpg

Measureable Benefits to Treat-to-Target Management in RA

d Jack Cush, MD

Desai and colleagues have published that when a learning collaborative group focused on a treat‐to‐target approach was compared to usual care, a modest but significant impact on implementation, treatment changes and patient outcomes in RA patients managed with a treat‐to‐target approach was seen.

Read Article
Cohort analysis of 12351 RA patients from CPRD registry - finds RA on both glucorticoids & PPI have a greater risk OP fractures (adj HR: 1.60, 95% CI: 1.35 to 1.89) vs non-use. Higher than the Fx Risk with either oral GC or PPI use alone (adj HR 1.2). https://t.co/oPMnJoHCjX https://t.co/eW7rpVeHa4

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective cohort study shows the risk of RA was lower in T2DM/diabetes (aHR 0.73; 95% CI 0.67–0.79) vs without T2DM. This risk was lost in when statins were not used (aHR 0.89; 0.69–1.14). Statins (in T2DM) had a protective effect against RA onset https://t.co/CfMJIuGOXI

Links:

Dr. John Cush RheumNow ( View Tweet)

We are excited to announce that Jeff Sparks ( @jeffsparks) will be leading a discussion on ILD in RA at RheumNow Live this March. Register to attend today. https://t.co/uwxOVh142F https://t.co/bnittqkhKQ

Links:

Dr. John Cush RheumNow ( View Tweet)
QD Clinics- The Sawtooth Steroid Taper Sawtooth Steroid Taper Surgery Rules for DMARDs & Biologics RA & DVT Traveling to Medical Meetings during COVID Hemoptysis and SLE When to do Genetic Testing in Febrile Patients https://t.co/dZLqGUyizG https://t.co/PYsH7K6ByB

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.